Compositions for treatment of systemic mastocytosis
US8076321B2 · kind B2 · utility
0Cited by
1References
15Claims
0Family size
Inventor
Key dates
| Filing date | Jul 19, 2006 |
| Grant date | Dec 13, 2011 |
| Priority date | — |
| Expiry date | Sep 15, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of the combination of tyrosine phosphate inhibitors AMN107 and PKC412 for the preparation of a drug for the treatment of a mast cell-related proliferative disease. The present invention is also drawn to a combination treatment of a tyrosine phosphate inhibitor and a TK-inhibitor that is effective against a mast cell-related proliferative disease, including especially systemic mastocytosis (SM) including aggressive SM (ASM) and mast cell leukemia (MCL).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.